Cyclic nucleotide analogs as carcinostatic agents

G. A. LePage, Evan M. Hersh

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Three cylcic nucleotide analogs, cyclic 3′,5′-arabinosyladenine monophosphate, cyclic 3′,5′-ribofuranosyl-6-mercaptopurine monophosphate and cyclic 3′,5′-ribofuranosyl-6-methylmercaptopurine monophosphate were tested for ability to penetrate murine tumor cells and human lymphocytes. Tests based on either tumor inhibition or inhibition of DNA synthesis in human lymphocytes undergoing blastogenesis, or both, indicated that these agents penetrated intact cells. It was demonstrated in one case (cAraMP) that the cells could convert the cyclic 3′,5′ nucleoside to 5′-nucleotide and that this had to occur intracellularly.

Original languageEnglish (US)
Pages (from-to)1918-1922
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume46
Issue number5
DOIs
StatePublished - Mar 10 1972

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Cyclic nucleotide analogs as carcinostatic agents'. Together they form a unique fingerprint.

  • Cite this